Akero Therapeutics Inc (AKRO)
28.09
-1.67
(-5.61%)
USD |
NASDAQ |
Nov 15, 16:00
28.09
0.00 (0.00%)
After-Hours: 20:00
Akero Therapeutics Research and Development Expense (TTM): 231.60M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 231.60M |
| June 30, 2024 | 198.00M |
| March 31, 2024 | 170.66M |
| December 31, 2023 | 141.80M |
| September 30, 2023 | 106.73M |
| June 30, 2023 | 93.18M |
| March 31, 2023 | 86.56M |
| December 31, 2022 | 85.28M |
| September 30, 2022 | 94.68M |
| June 30, 2022 | 89.06M |
| March 31, 2022 | 91.67M |
| December 31, 2021 | 81.76M |
| Date | Value |
|---|---|
| September 30, 2021 | 79.76M |
| June 30, 2021 | 77.67M |
| March 31, 2021 | 66.73M |
| December 31, 2020 | 64.92M |
| September 30, 2020 | 52.34M |
| June 30, 2020 | 48.85M |
| March 31, 2020 | 41.77M |
| December 31, 2019 | 37.05M |
| September 30, 2019 | 25.89M |
| June 30, 2019 | 13.26M |
| March 31, 2019 | 15.72M |
| December 31, 2018 | 11.88M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
37.05M
Minimum
Dec 2019
231.60M
Maximum
Sep 2024
97.00M
Average
85.92M
Median
Research and Development Expense (TTM) Benchmarks
| Madrigal Pharmaceuticals Inc | 281.71M |
| 89bio Inc | 267.33M |
| NovaBay Pharmaceuticals Inc | 0.064M |
| Palatin Technologies Inc | 22.40M |
| iBio Inc | 5.185M |